Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose methylprednisolone for alkaline caustic esophageal burns in children
IRCT20260508069286N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of methylprednisolone in caustic esophagitis (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Esophageal stricture, Rate of hospitalization and 1 more. Started Jun 2026; status: completed.
02
Drugs
methylprednisolone
03
Conditions
caustic esophagitis
Beyond the preview
Go deeper on IRCT20260508069286N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260508069286N1.